0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

Physician-Industry Interactions and Anti–Vascular Endothelial Growth Factor Use Among US Ophthalmologists

Paul R. Lichter, MD1
[+] Author Affiliations
1Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor
JAMA Ophthalmol. 2016;134(8):903-904. doi:10.1001/jamaophthalmol.2016.1794.
Text Size: A A A
Published online

Extract

In this issue of JAMA Ophthalmology, Taylor et al1 have used the Centers for Medicare & Medicaid Services (CMS) Open Payments program 2013 database, which provides mandatory reporting data from companies on payments they make to physicians, and the CMS 2013 Provider Utilization and Payment Data: Physician and Other Supplier Public Use File in an innovative manner to assess the putative effect on drug use of payments from Genentech and Regeneron Pharmaceuticals to physicians targeted to those companies’ specific anti–vascular endothelial growth factor (VEGF) drugs. Specifically, the authors compared physicians’ use of ranibizumab and aflibercept with their use of bevacizumab for intravitreous injections. They found that pharmaceutical industry financial incentives to physicians, obviously given to influence prescribing behavior, are strongly correlated with that behavior, namely, prescribing the most expensive anti-VEGF drugs for intravitreous injection when a far less expensive alternative is equally effective. Although the authors were unable to attribute cause and effect to their findings, it makes sense that cause and effect may well exist.

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

351 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
Jobs
brightcove.createExperiences();